Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Semaglutide, the main ingredient in Ozempic and Wegovy, is in ongoing shortage, the FDA says, and compounded versions of these drugs are still permitted. The U.S. Food and Drug Administration (FDA ...

A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or ...

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.